Columna Capital’s exit from Ardentis Cliniques Dentaires underscores a familiar playbook in European healthcare: build regional density in a fragmented provider market, then hand the platform to a larger strategic group with distribution and balance-sheet advantages.
Medbase, the healthcare network owned by Migros, acquired a majority stake in Ardentis in August 2026. Financial terms were not disclosed. Ardentis’s management retained a significant minority stake and stayed in place, with Medbase becoming the new majority shareholder.
A platform built for consolidation
Columna has been explicit about its strategy in the segment: continue consolidating the fragmented dental care market in Western Switzerland by adding capacity to existing clinics and through targeted acquisitions. Ardentis fits that template.
Founded in 1993, Ardentis has grown into one of the leading providers of dental services in French-speaking Switzerland. The business now operates 20 clinics across Switzerland, up from 12 clinics in 2018, pointing to sustained platform expansion over multiple years rather than a one-off build.
Operationally, Ardentis has meaningful scale for a provider roll-up: recent reporting puts headcount at about 450 employees and patient volume at roughly 70,000 patients per year. The footprint is concentrated in urban locations across French-speaking Switzerland, suggesting a structured regional network with repeatable clinic operations instead of a loose federation of practices.
Why Medbase, why now
The buyer profile matters. Medbase is positioned as a broader healthcare group, and the transaction was framed as strengthening its position in Swiss healthcare. That is consistent with a strategic acquirer’s rationale: add a scaled dental vertical to an existing network and use brand, referral pathways, and shared infrastructure to accelerate growth.
Key questions for the integration thesis include:
- Go-to-market overlap and referral logic: how Medbase plans to connect dental services with its wider outpatient network without diluting Ardentis’s clinic-level conversion and patient experience.
- Systems and operating cadence: whether Ardentis’s clinic operations, scheduling, billing, and procurement can be integrated into Medbase’s standards without disrupting chair utilization and clinician productivity.
- Leadership depth and execution bandwidth: management remains in place with a minority stake, which can protect continuity, but it also raises the question of how decision rights will be structured as Medbase scales the platform.
What the exit signals for Swiss dental
This deal adds to evidence that Swiss dental is moving further along the consolidation curve. A scaled regional platform in French-speaking Switzerland moving into the hands of a larger healthcare group suggests that strategic buyers see dentistry as an adjacency worth owning, not just partnering with.
For sponsors and operator-builders, the transaction reinforces two themes:
- Density wins: Ardentis’s urban concentration and multi-clinic footprint likely improved unit economics and made the asset easier to underwrite as a network.
- Strategic endpoints remain open: the sale to Medbase indicates that scaled healthcare groups are active buyers of provider platforms when the assets reach operational maturity.
With price and structure undisclosed beyond the majority-stake transfer, it remains unclear how the market is valuing Swiss dental platforms today, or how much of the equity story was driven by organic growth versus bolt-ons during Columna’s hold.
What to watch next
- Whether Medbase keeps Ardentis as a distinct brand or moves toward a unified network offering
- Any follow-on clinic acquisitions in Western Switzerland under Medbase ownership
- Integration milestones: IT, procurement, and shared services, and their impact on clinic throughput
- Retention of clinicians and key managers as governance shifts to a strategic majority owner
- Signs of broader Swiss dental consolidation as other healthcare groups respond